Gateff C, Dodin A, Wiart J
Ann Microbiol (Paris). 1975 Feb-Mar;126(2):231-46.
In order to test whether simultaneously administered cholera vaccine has a depressive effect on yellow fever vaccine, a controlled trial was undertaken on school-age children in the South-Central Province of Cameroun. In addition to this principle objective, the study also permitted a comparison of the serological response in subjects vaccinated with classical cholera vaccine and in those vaccinated with a purified fraction vaccine, either with or without simultaneous yellow fever vaccine. The evaluation was measured by changes in vibriocidal antibodies and cholera agglutinins 30 days after vaccination. Only subjects without cholera antibodies prior to the study, were included. 1) Results obtained by assay of vibriocidal antibodies. It was confirmed that, no matter which cholera vaccine was used, the simultaneous administration of yellow fever vaccine had no influence on the percentage of subjects showing a significant rise in vibriocidal antibodies (4-fold increase in titre) following vaccination. In addition, in this study the purified fraction vaccine resulted in a significantly higher rate of seroconversion than did the classical vaccine. However, in comparison to other studies using classical cholera vaccine, our figures for seroconversion after purified fraction vaccine show very little, if any, differences. 2) Results obtained by assay of agglutinating antibodies. When measured by this method, there was a high frequency of non-reactors to the vaccines. This may be attributed to the date of the post vaccination blood speciment (30th day after vaccination). It has been shown that agglutinins decay rapidly after the 15th day following clinical cholera. Thus, the late date of the second speciment after vaccination could explain why we were unable to show any difference in the level of agglutinin after either classical or purified cholera vaccination. The simultaneous administration of the yellow fever vaccine did not influence the titre of agglutinins induced by the classic cholera vaccine. On the other hand, using the association, the seroconversion rate as observed on the 30th day post vaccination was significantly higher than that observed when the fraction was administered alone. If one accepts the generally admitted specificity of the agglutination reaction after clinical disease, two hypotheses can be considered: a) the yellow fever vaccine has an adjuvant effect for the production of antibodies induced by the purified fraction vaccine, or b) the addition of yellow fever vaccine has a retarding effect on the elimination of the agglutinins which, in the natural disease, are rapidly eliminated. Further studies to verify these hypothesis should be undertaken.
为了测试同时接种霍乱疫苗是否会对黄热病疫苗产生抑制作用，在喀麦隆中南部省份的学龄儿童中进行了一项对照试验。除了这一主要目的外，该研究还比较了接种传统霍乱疫苗和纯化组分疫苗的受试者在接种或未接种黄热病疫苗时的血清学反应。评估通过接种疫苗30天后杀弧菌抗体和霍乱凝集素的变化来衡量。仅纳入研究前无霍乱抗体的受试者。1） 通过检测杀弧菌抗体获得的结果。证实无论使用哪种霍乱疫苗，同时接种黄热病疫苗对接种后杀弧菌抗体显著升高（滴度增加4倍）的受试者百分比均无影响。此外，在本研究中，纯化组分疫苗的血清转化率显著高于传统疫苗。然而，与其他使用传统霍乱疫苗的研究相比，我们关于纯化组分疫苗后血清转化率的数据即使有差异也非常小。2） 通过检测凝集抗体获得的结果。用这种方法检测时，疫苗无反应者的频率较高。这可能归因于接种后采血样本的日期（接种后第30天）。已经表明，凝集素在临床霍乱后第15天迅速衰减。因此，接种后第二次样本采集时间较晚可以解释为什么我们未能显示传统或纯化霍乱疫苗接种后凝集素水平有任何差异。同时接种黄热病疫苗不影响传统霍乱疫苗诱导的凝集素滴度。另一方面，联合使用时，接种后第30天观察到的血清转化率显著高于单独接种纯化组分疫苗时观察到的血清转化率。如果接受临床疾病后凝集反应普遍公认的特异性，可以考虑两个假设：a）黄热病疫苗对纯化组分疫苗诱导的抗体产生有佐剂作用，或b）添加黄热病疫苗对凝集素的消除有延缓作用，而在自然疾病中凝集素会迅速消除。应进行进一步研究以验证这些假设。
